Why the study?
Does ranolazine prevent postoperative atrial fibrillation in patients after cardiac surgery?
Does ranolazine prevent postoperative atrial fibrillation in patients after cardiac surgery?
Ranolazine may be an effective therapy for preventing postoperative atrial fibrillation following cardiac surgery, though larger randomized trials are needed to confirm efficacy.
Ranolazine may prevent POAF after cardiac surgery; extends limited evidence but leaves open need for confirmatory large RCTs.
Postoperative atrial fibrillation (POAF) remains a major risk after cardiac surgery and is associated with an increased risk of stroke, length of stay, mortality, and cost. Ranolazine, an anti-anginal drug, also has anti-arrhythmic properties. The present study is to evaluate the effectiveness of ranolazine in preventing POAF after cardiac surgery. We searched the literature for clinical studies published up to August 2017 with a pre-defined inclusion and exclusion criteria. We identified four studies with a total of 754 patients of which 300 patients received ranolazine; there was a 14% decrease in POAF occurrence following cardiac surgery compared to 32% in the control group. Although ranolazine is an effective therapy in prevention of POAF, larger, multi-center, randomized trials are warranted.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: